Viking Therapeutics Stock News

The three top performing stocks discussed below have appreciated in value by an average of 129.7% in 2024. Such torrid growth logically raises the question of what is possible moving forward.

Though obesity drugs continue to gain traction, it is currently a duopoly market. As analysts expect demand to grow at an encouraging pace, several biotech/pharma companies are rushing to enter this s

Viking's GLP-1 inhibitor candidate has shown promise for weight loss in clinical trials. But investors should keep in mind that the company has no approved products yet.

With innovation, millions of retiring baby boomers, demand for better care, patent cliffs, gene-editing, massive interest in weight-loss treatments, and an increase in mergers, biotech stocks to buy h

The mega-cap tech stocks have garnered much attention in recent months. However, certain smaller companies have also performed well, with some small-cap stocks to buy showing promise for growth.

Viking Therapeutics' (VKTX) lead candidate for obesity, VK2735, is expected to have tremendous potential. However, existing competition from obesity drugs in the market remains a woe.

If you're wondering what stocks to buy this month, look no further. Every investor wants their stock picks to double in price.

Viking Therapeutics has been one of the hottest biopharma stocks in 2024. Even so, the market may be seriously underestimating the company's true value proposition.

Viking has what could be a best-in-class asset for treating obesity. It also has some powerful competitors to face that have a strong lead.

Viking Therapeutics' subcutaneously administered version of VK2735 has generated competitive data in the phase 2 trial in obese patients. The oral formulation of VK2735 reported good tolerability that

Investing in Russell 2000 stocks is a smart idea because it focuses on small-cap stocks with substantial growth potential. While individual stocks within the index vary, some are poised to offer signi

Investors are well aware of the explosive growth potential in weight loss drug stocks. That growth began last year with Eli Lilly (NYSE: LLY ) and Novo Nordisk (NYSE: NVO ).

Amid a challenging market environment, one of your best bets could be to target biotech stocks to buy. Yes, the sector can be volatile because much hinges on underlying breakthroughs.

Amgen, Viking Therapeutics, Altimmune, AstraZeneca, Boehringer Ingelheim and Zealand Pharma are making encouraging progress on their own treatments.

According to Harvard University, about two-thirds of United States adults are “overweight or obese,” while 36% are obese. And the university predicts that, at the current rate, about 50% of Americ